Directorio

We are doing this study to learn more about the immune response patients with X-linked Agammaglobulinemia (XLA) have to COVID-19 vaccination. We will compare their immune responses to those of healthy people who have normal immune systems. Better understanding of cellular responses to COVID-19 vaccines by XLA patients is important since XLA patients cannot make antibodies to vaccines. If you are interested, please contact the study team at XLACOVIDvax@duke.edu.

We are doing this study to better understand how breast cancer treatment can affect the heart. In particular, we want to know if treatment with near complete estrogen deprivation (NCED) therapy has an impact on heart function.

We are doing this study to find out if an experimental drug called CTX131 (the study drug) is a safe and effective treatment for different forms of cancer with solid tumors. The study drug is made from white blood cells or T cells from healthy donors.

We are doing this study to find out if using ice with or without compression during chemotherapy can prevent neuropathy for patients being treated for gynecologic cancer.

We are doing this study to find out if an experimental product called cryopreserved platelets (CPP) can help control the bleeding that happens during and after cardiopulmonary bypass surgery. We want to see how well this product works in comparison to the standard therapy that is used to control bleeding during surgery, which is liquid stored platelets (LSP).

We are doing this study to collect cerebrospinal fluid (CSF) samples from people with cancer that has spread to the leptomeninges (the inner membranes that cover the brain and spinal cord). These CSF samples will be used in laboratory research projects to identify substances called biomarkers. Biomarker testing is a way to look for genes, proteins, and other substances (tumor markers) that can provide information about cancer. Information from these CSF samples may help us learn about new methods to treat metastatic disease to the leptomeninges.

We are doing this study learn more about circulating immune cells and circulating tumor cells (CTCs) in patients with metastatic renal cell carcinoma or metastatic urothelial carcinoma. We are also looking at the bacteria in your gut and urinary tract to learn about how these bacteria affect how your cancer responds to immunotherapy.

We are doing this study to find out if an investigational drug called tocilizumab (the study drug) will lead to better outcomes after lung transplantation when it is combined with standard anti-rejection medicines.